Researchers in France found that children were 2.6 times more likely to become ill with acute lymphoblastic leukaemia (ALL), the most common type of childhood leukaemia, if their mothers had been treated with ovary-stimulating drugs.
They had a 2.3-fold increased risk of suffering the rarer form of the disease, acute myeloid leukaemia (AML). Children conceived naturally after their mothers waited over a year to get pregnant had a 50 per cent greater-than-normal likelihood of developing ALL, the 'Daily Mail' reported.
But, no heightened risk of childhood leukaemia was associated either with in-vitro fertilisation or artificial insemination, say the researchers.
"It has always been hypothesised that assisted reproductive technologies may be involved in the onset of childhood cancer as they involve repeated treatment at the time of conception and or manipulation of the sperm and egg. And it is now established that a majority of acute leukaemia have a pre-natal (pre-birth) origin.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
